Journal
JOURNAL OF CELLULAR PHYSIOLOGY
Volume 233, Issue 12, Pages 9136-9144Publisher
WILEY
DOI: 10.1002/jcp.26847
Keywords
breast cancer; cancer stem cell (CSC); epithelial-to-mesenchymal transition (EMT); tumor heterogeneity
Categories
Funding
- Charlotte Coleman Fund for Cancer Research
- Foundation for the National Institutes of Health [P01 082834]
- NIH NCI [1F32CA220935]
Ask authors/readers for more resources
Breast cancer is the most common cancer in women, and accounts for similar to 30% of new cancer cases and 15% of cancer-related deaths. Tumor relapse and metastasis are primary factors contributing to breast cancer-related deaths. Therefore, the challenge for breast cancer treatment is to sustain remission. A driving force behind tumor relapse is breast cancer heterogeneity (both intertumor, between different patients, and intratumor, within the same tumor). Understanding breast cancer heterogeneity is necessary to develop preventive interventions and targeted therapies. A recently emerging concept is that intratumor heterogeneity is driven by cancer stem cells (CSCs) that are capable of giving rise to a multitude of different cells within a tumor. Studies have highlighted linkage of CSC formation with epithelial-to-mesenchymal transition (EMT). In this review, we summarize the current understanding of breast cancer heterogeneity, links between EMT and CSCs, regulation of EMT by Runx transcription factors, and potential therapeutic strategies targeting these processes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available